Evidence map›Paper›PMID 39099800›Full record

ArticleResearch and practice in thrombosis and haemostasis2024

Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study.

Jennifer Light, Christina M Abrams, Anton Ilich, Shuai Huang, Hongtu Zhu, Jacquelyn Baskin-Miller, Erica M Sparkenbaugh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Sickle cell disease: managing thromboembolism.Hematology. American Society of Hematology. Education Program · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jennifer LightDivision of Hematology, Department of Medicine, Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Christina M AbramsDivision of Hematology/Oncology, Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.
Anton IlichDivision of Hematology, Department of Medicine, Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Shuai HuangDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Hongtu ZhuDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jacquelyn Baskin-MillerDivision of Hematology, Department of Medicine, Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Erica M SparkenbaughDivision of Hematology, Department of Medicine, Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Funding

Biased PAR1 Agonism in Sickle Cell DiseaseR01HL155193 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SPARKENBAUGH, ERICA M · 2021 to 2025
$1.9M
NHLBI NIH HHS R01 HL155193
6 · The paper itself

Abstract

Background: Estrogen-containing hormonal contraception (HC) is a well-established risk factor for venous thromboembolism (VTE). Women with sickle cell disease (SCD) also have an increased risk of VTE. However, it is unknown if exposure to HC exacerbates the risk of VTE in women with SCD. Objectives: Assess the impact of HC on VTE risk in women with SCD and explore additional risk factors contributing to VTE development. Methods: We analyzed a retrospective cohort of women of reproductive age (15-49 years) with SCD at the University of North Carolina from 2010 to 2022. Results: We identified 370 women with SCD, and 93 (25.1%) had a history of VTE. Among 219 women exposed to HC, 38 of 184 (20.6%) had a VTE while actively using HC, whereas 20 of 151 (13.2%) women never exposed to HC had a VTE. Of the patients exposed to HC, 64 of 184 (34.7%) were on estrogen-containing HC, with 120 of 184 (65.3%) using progestin-only formulations. Cox regression analysis found that progestin-only formulations increased VTE risk (hazard ratio: 2.03; 95% CI: 1.107-3.726, Conclusion: Overall, we found that increased thrombotic risk is more likely influenced by disease status than HC exposure and should play a role in shared decision-making with patients.

Indexed as

contraceptionestrogen-containing contraceptionprogesterone-only contraceptionpulmonary embolismsickle cell diseasevenous thrombosiswomen’s health

Identifiers

PMID39099800
PMCPMC11295566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.